advertisement
Abstract #14204 Published in IGR 8-3
Intraocular pressure-lovering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma
Chew PTK; Pongpun PR; Euswas A; Lu D-W; Chua J; Hui S-P; Rait J; Goldberg I; Li BAsian Journal of Ophthalmology 2006; 8: 13-19
AIM: To compare the intraocular pressure-lowering efficacy and safety of travoprost 0.004% with latanoprost 0.005% for patients with chronic angle closure glaucoma. PATIENTS AND METHODS: 320 patients with chronic angle closure glaucoma, who had previously undergone laser peripheral iridotomy, were randomised to receive travoprost 0.004% once daily (n = 161) or latanoprost 0.005% (n = 159) once daily for 12 weeks. Efficacy and safety evaluations were conducted on day 2, and weeks 2, 6, and 12. Intraocular pressure measurements were performed at 9.00 am and 4.00 pm, except at the week 6 visit, when the intraocular pressure was measured at 9.00 am only. RESULTS: Mean intraocular pressure reductions from baseline were up to 9.1 mmHg (95% confidence interval, -9.7, -8.4) and 7.9 mmHg (95% confidence interval, -8.5, -7.3) with travoprost and latanoprost, respectively. Pooled intraocular pressure data for the 12-week period suggested that travoprost was more efficacious than latanoprost at 9.00 am, but this was not statistically significant. At 4.00 pm, pooled intraocular pressure data for the intent-to-treat analysis demonstrated a statistically superior reduction for travoprost compared with latanoprost (p = 0.0196). Travoprost 0.004% also demonstrated significantly greater intraocular pressure reduction from baseline than latanoprost in the per protocol analysis at 4.00 pm (p = 0.0162). Up to 71% of patients treated with travoprost and up to 63% of patients treated with latanoprost achieved a target intraocular pressure of < 18 mmHg during the 12-week study period. No treatment-related serious adverse events were reported in either group. CONCLUSION: Both travoprost and latanoprost are effective for control of intraocular pressure in patients with chronic angle closure glaucoma. Travoprost 0.004% provided equal or greater intraocular pressure control than latanoprost 0.005%. Once daily administration was well tolerated by patients with chronic angle closure glaucoma.
Dr. B. Li, Alcon (China) Ophthalmic Product Co., Ltd., No. 3 West Maizadian Road, Chaoyang District, Beijing 100016, China
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
